AI Article Synopsis

  • The study investigates whether reducing heart rate (HR) during hospitalization affects death or rehospitalization rates in heart failure patients.
  • The analysis included 747 patients, with 65.7% experiencing HR reduction; however, there was no significant difference in 1-year mortality or rehospitalization rates between those with reduced HR and those without.
  • Independent predictors for poor outcomes varied between groups, emphasizing the complexity of heart failure management rather than a direct correlation with HR reduction.

Article Abstract

Background: Currently, there is no information on whether in-hospital heart rate (HR) reduction has an influence on risk of death or rehospitalization. The study evaluates the relation between inhospital HR reduction in heart failure (HF) patients on mortality and rehospitalization within 1-year observation.

Methods: The analysis included patients hospitalized in Poland with sinus rhythm from the European Society of Cardiology Heart Failure Pilot (ESC-HF-Pilot) and ESC Heart Failure Long-Term Registries (ESC-HF-LT), who were divided into two groups: reduced HR and not-reduced HR. HR reduction was defined as a reduced value of HR at discharge compared to admission HR. The primary endpoint was 1-year all-cause death, the secondary endpoint was 1-year all-cause death or rehospitalization for worsening HF.

Results: The final analysis included 747 patients; 491 reduced HR (65.7%) and 256 not-reduced HR (34.3%). The primary endpoint occurred in 58/476 (12.2%) from reduced HR group and in 26/246 (10.5%) from not-reduced HR group (p = 0.54). In the reduced HR group, independent predictors of primary endpoint were age, New York Heart Association class at admission, serum sodium level at admission and systolic blood pressure at discharge. In the not-reduced HR group the independent predictor of primary endpoint was diastolic blood pressure at discharge. The secondary endpoint was observed in 180 patients, 124/398 (31.2%) from reduced HR and 56/207 (27.1%) from the not-reduced HR group (p = 0.30). In the not-reduced HR group only angiotensin converting-enzyme inhibitor usage at discharge was independently associated with lower risk of the secondary endpoint.

Conclusions: In-hospital HR reduction did not influence on the outcomes of HF patients in sinus rhythm.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086505PMC
http://dx.doi.org/10.5603/CJ.a2018.0094DOI Listing

Publication Analysis

Top Keywords

heart failure
20
primary endpoint
16
not-reduced group
16
sinus rhythm
12
in-hospital heart
8
heart rate
8
rate reduction
8
failure patients
8
patients sinus
8
european society
8

Similar Publications

Background: The impact of iron deficiency on COPD morbidity independent of anemia status is unknown. Understanding the association between iron deficiency, anemia status, and risk of hospitalization in COPD may inform an approach to these comorbidities.

Study Design And Methods: Adults ≥40 years from the Johns Hopkins COPD Precision Medicine Center of Excellence data repository with an outpatient iron profile and 1 year of subsequent follow-up time were included in the study.

View Article and Find Full Text PDF

chitinase-like protein orchestrates cyst wall glycosylation to facilitate effector export and cyst turnover.

Proc Natl Acad Sci U S A

February 2025

Department of Molecular Microbiology, Washington University in St. Louis, School of Medicine, St. Louis, MO 63130.

bradyzoites reside in tissue cysts that undergo cycles of expansion, rupture, and release to foster chronic infection. The glycosylated cyst wall acts as a protective barrier, although the processes responsible for formation, remodeling, and turnover are not understood. Herein, we identify a noncanonical chitinase-like enzyme TgCLP1 that localizes to micronemes and is targeted to the cyst wall after secretion.

View Article and Find Full Text PDF

Background: Myocardial ischemia-reperfusion injury (MIRI) is an important complication in the treatment of heart failure, and its treatment has not made satisfactory progress. Nitroxyl (HNO) showed protective effects on the heart failure, however, the effect and underlying mechanism of HNO on MIRI remain largely unclear.

Methods: MIRI model in this study was established to induce H9C2 cell injury through hypoxia/reoxygenation (H/R) in vitro.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!